




Conclusions, news, and next







Conclusions, news, and next



What factors for the Gardasil price?

When do R&D costs matter?

- Before R&D costs are paid, they matter
 - Firms typically need to expect a high price in order to invest
- After R&D costs are paid, they don't matter
 - Sunk costs don't matter

R&D costs versus revenue

- For successful drugs, R&D costs << revenue
- (For failed drugs, R&D costs >> revenue = \$0)
- So industry critics want reporting of R&D costs
- And firms refuse

What US price for Gardasil?

• <\$120

>\$120

What price in India?

• <\$50 • >\$50

If price=\$120/dose, what is cost per QALY?

Assumptions (Source: Calkins 2009)

- 3 Doses
- \$120 Price/dose
 - \$20 Administration fee
 - 0 Alternative
- 0.6% Probability cervical cancer if no Gardasil
- 70% Probability cancer prevented by Gardasil
 - 0.8 QALY per year
- 81.6 Years of life with Gardasil
 - 70 Years of life without Gardasil
 - ? Cost per QALY

If price is \$120/dose, what is cost per QALY?

Assumptions (Source: Calkins 2009)

3 Doses

\$120 Price/dose

\$20 Administration fee

0 Alternative

0.6% Probability cervical cancer if no Gardasil

70% Probability cancer prevented by Gardasil

0.8 QALY per year

81.6 Years of life with Gardasil

70 Years of life without Gardasil

? Cost per QALY

Change in cost Change in QALY

3*(\$120+\$20) - 0 0.006*0.7*0.8*(81.6-70) QALY

> \$420 0.039 QALY

\$11,000/QALY

\$26,000/QALY if 3% discount and 30 years =\$11K/(1/1.03)^30

Also cost savings from not treating cancer, but distant future

If year worth \$50,000, what is max price?

Assumptions		Change in cost	<	
3	Doses	<u> </u>	= \$	
?	Price/dose	Change in QALY		
\$20	Administration fee			
0	Alternative	<u>3*(price+\$20) – 0</u>	= \$	
0.6%	Probability cervical cancer if no Gardasil	0.006*0.7*0.8*(81.6-70)Q	ΔΙΥ	
70%	Probability cancer prevented by Gardasil	0.000 0.7 0.0 (01.0 70)	,	
0.8	QALY per year			
81.6	Years of life with Gardasil	\$60+3*price	_ ~	
70	Years of life without Gardasil	0.039 QALY	= \$	
\$50,000	Cost per QALY	3,333 3, 121		

Price < \$630/dose

= \$50,000

= \$50,000

= \$50,000

US price for Gardasil

- US launch price = \$125/dose
- Cost effective
- Highest US vaccine price

Manufac.	Brand	CDC Price	Private Price
	Gardasil	\$101	\$125
	ProQuad	\$81	\$124
	Varivax	\$62	\$78
	RotaTeq	\$57	\$70
Merck	COMVAX	\$29	\$44
	RECOMBIVAX HB	\$24	\$59
	MMRII	\$18	\$47
	VAQTA	\$13	\$30
	PedvaxHIB	\$11	\$23
	Menactra	\$76	\$94
	Pentacel	\$50	\$73
	ADACEL	\$31	\$37
	TriHIBit	\$27	\$43
Sanofi	DECAVAC	\$17	\$19
	DAPTACEL	\$13	\$22
	Tripedia	\$13	\$21
	IPOL	\$11	\$23
	ActHIB	\$9	\$22

\$125 2008

Manufac.	Brand	CDC Price	Private Price
	Rotarix	\$82	\$103
	Pediarix	\$49	\$71
	Twinrix	\$39	\$78
CCK	Kinrix	\$32	\$48
GSK	BOOSTRIX	\$31	\$36
	Infanrix	\$14	\$21
	Havrix	\$12	\$27
	ENGERIX B	\$10	\$21
Wyeth/Lederle	Prevnar	\$66	\$84

Source: Centers for Disease Control (CDC). September 2008 Higher price of adult and ped. Excludes influenza which is about \$20

Maker	Vaccine	Brand	CDC Price		Private Pr	
	DTaP-IPV-HIB-HEPB	Vaxelis	\$	98	\$	151
	Нер А	Vaqta	\$	40	\$	79
	Нер В	Recombivax HB	\$	32	\$	67
	Hib	PedvaxHIB	\$	16	\$	30
	HPV 9-valent	Gardasil9	\$	225	\$	288
Merck	MMR	M-M-RII	\$	61	\$	92
	MMR/Varicella	ProQuad	\$	165	\$	270
	Pneumo 15-valent	Vaxneuvance	\$	162	\$	223
	Pneumo 23-valent	Pneumovax23	\$	82	\$	117
	Rotavirus	RotaTeq	\$	79	\$	96
	Varicella	Varivax	\$	132	\$	174
	Dengue	Dengvaxia	\$	96	\$	104
	DTaP	Daptacel	\$	21	\$	29
	DTaP-IP-HI	Pentacel	\$	68	\$	115
	DTaP-IPV	Quadracel	\$	46	\$	62
C	e-IPV	IPOL	\$	16	\$	43
	Hib	ActHIB	\$	11	\$	13
	Meningococcal	MenQuadfi	\$	108	\$	167
	RSV	Beyfortus	\$	395	\$	495
	DT	Tenivac	\$	23	\$	37
	DTaP	Adacel	\$	36	\$	48

\$288 for 2 2024


Maker	Vaccine	Brand	CDC	Price	Private	Price
	DTaP	Infanrix	\$	21	\$	29
	DTaP-Hep B-IPV	Pediarix	\$	64	\$	98
	DTaP-IPV	Kinrix	\$	47	\$	61
	Нер А	Havrix	\$	39	\$	83
	Нер А-Нер В	Twinrix	\$	76	\$	126
	Нер В	Engerix-B	\$	36	\$	69
GSK	Hib	Hiberix	\$	11	\$	13
GSK	MMR	Priorix	\$	61	\$	92
	Meningococcal B	Bexsero	\$	142	\$	224
	Meningococcal	Menveo one-vial	\$	106	\$	157
	RSV	Arexvy	\$	198	\$	280
	Rotavirus	Rotarix	\$	105	\$	139
	DTaP	Boostrix	\$	36	\$	47
	Zoster	Shingrix	\$	121	\$	198
Dynavax	Нер В	Heplisav-B	\$	75	\$	141
Grifols	DT	TDVAX	\$	19	\$	28
Moderna	Covid-19	Spikevax	\$	86	\$	128
	Covid-19	Comirnaty	\$	98	\$	115
Pfizer	Meningococcal B	Trumenba	\$	131	\$	179
FIIZEI	Pneumo 20-valent	Prevnar 20	\$	178	\$	253
	RSV	Abrysvo	\$	227	\$	295
VBI	Нер В	PreHevbrio	\$	34	\$	66

Source: Centers for Disease Control (CDC). March 2024 Higher price of adult and ped. Excludes influenza which is about \$20

Vaccines for Children Program


- Allocated by Centers for Disease Control and Prevention (CDC)
- Pays for about 1/2 of childhood vaccines in US
- Children (≤ 18) eligible if
 - Medicaid
 - Uninsured
 - American Indian or Alaska Native
 - Underinsured
- Includes flu, human papillomavirus, measles, ...

Gardasil revenue



Source: Ridley using data from Merck SEC 10K filings

Global vaccine makers, 2019



Source: World Health Organization report using 2019 data.

SII = Serum Institute of India. BBIL = Bharat Biotech International Limited

1. Cost-effectiveness \(\triangle \) \(\tri



Conclusions, news, and next




Global market

Incidence of Cervical Cancer

Indidence ASR Female Cervix uteri cancer 30.2+ 20.6-30.2 13.6-20.6 7.9-13.6 7.9 No Data International Agency for Research on Cancer Source: GLOBOCAN 2012 (IARC) World Health Organization


Incidence of Breast Cancer



Source: International Agency for Research on Cancer

"Médecins Sans Frontières/Doctors Without Borders (MSF) ... showed that in the poorest countries, the price to vaccinate a child is now a colossal 68 times more expensive than it was in 2001..."

- Stephen Cornish in Huffington Post



Source: Médecins Sans Frontières

Gardasil price per dose as low as \$4.50



Source: Médecins Sans Frontières, 2014

Low prices in low-income countries

Price	Price Maker		Disease	
\$0	Merck	Ivermectin	River blindness	
\$5	Merck	Gardasil	Human papillomavi rus	
License to generics	Gilead	Sovaldi	Hepatitis C	





Conclusions, news, and next



3 Conclusions

- Choose price based on value, but also political and ethical considerations.
- 2. Charge low prices in low-income countries.
- 3. If you make an important product, you'll make money and get attention, including from Médecins Sans Frontières.

Next

- Class photo
- Which should Teva make: innovators, generics, or biosimilars?
- What is the current state of the biosimilar market?

Pfizer Revenue

